Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1988-02-17
1994-06-21
Lovering, Richard D.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
424 149, 424 8591, 5303913, 5303915, 5303917, 530402, 530410, A61K 4300, A61K 39395
Patent
active
053226780
ABSTRACT:
There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic agent at the target site. Conversely, charge-modification to cause a basic shift in the isoelectric point of the conjugate reduces serum half-life upon in vivo use for diagnostic imaging purposes and results in higher target-to-background ratios.
REFERENCES:
patent: 3720765 (1973-03-01), Miller
patent: 4082507 (1978-04-01), Sawyer
patent: 4118379 (1978-10-01), Schmidtberger
patent: 4168262 (1979-09-01), Kinsella et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4218539 (1980-08-01), Weltman
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4414147 (1983-11-01), Klibanov et al.
patent: 4493829 (1985-01-01), Sportoletti et al.
patent: 4501692 (1985-02-01), Gibbons et al.
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4560504 (1985-12-01), Arnold
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4749570 (1988-06-01), Poznansky
patent: 4766106 (1988-08-01), Katre et al.
patent: 4847325 (1988-07-01), Shadle et al.
patent: 4870162 (1989-09-01), Trouet et al.
patent: 4885153 (1989-12-01), Wilbur et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4931544 (1990-06-01), Katre et al.
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5055289 (1991-10-01), Frincke et al.
patent: 5084556 (1992-01-01), Brown
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5109120 (1992-04-01), Ueno et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5151266 (1992-09-01), Morgan, Jr. et al.
patent: 5162505 (1992-11-01), Dean et al.
patent: 5223242 (1993-06-01), Khaw et al.
European Search Report and Annex thereto for European Patent Application No. EP 89 10 2810.
Torchilin et al., Hybridoma, vol. 6, No. 3, 1987, pp. 229-240, "Monoclonal Antibody Modification with Chelate-Linked High Molecular-Weight Polymers: Major Increases in Polyvalent Cation Binding Without Loss of Antigen Binding".
Vogt et al., Kidney International, vol. 22, 1982, pp. 27-35, "Interaction of Cationized Antigen with Rat Glomerular Basement Membrane: In Situ Immune Complex Formation".
Rutter and Wade, Br. J. exp. Path., 52, 1971, pp. 610-614, "The Influence of the Iso-Electric Point of L-Asparaginase Upon its Persistence in the Blood".
Holcenberg et al., Cancer Research, 39, Aug. 1979, pp. 3145-3151, "Human Pharmacology and Toxicology of Succinylated Acinetobacter Glutaminase-Asparaginase".
Holcenberg et al., The Journal of Bioloigcal Chemistry, Jun. 10, 1975, vol. 250, No. 11, pp. 4165-4170, "Biologic and Physical Properties of Succinylated and Glycosylated Acinetobacter Glyutaminase-Asparaginase".
Boyd et al., Int. J. Peptide Protein Res., 1972, vol. 4, pp. 117-122, "N-Acylsuccinimdes as Acylating Agents for Proteins: The Selective Acylation of Lysine Residues".
DeRiemer et al., "BLEDTA: Tumor Localization by a Bleomycin Analogue Containing a Metal-Chelating Group," J. Med. Chem. 22:1019-23 (1979).
Mannik et al., "Immune Complexes with Cationic Antibodies Deposit in Glomeruli More Effectively than Cationic Antibodies Alone," J. Immunol., 38:4209-17 (1987).
Meighen et al., "Hybridization of Native and Chemically Modified Enzymes. I. Development of a General Method and its Application to the Study of the Subunit Structure of Aldolese," Biochemistry 9:1163-76 (1970).
Hartley, "Strategy and Tactics in Protein Chemistry," Biochem. J. 119:805-22 (1970).
Chu et al., "Chemical Modification of Amino Groups in Staphylococcal Enterotoxin B," Biochemistry, 8:2890-96 (1969).
Deen et al., "Heteroporous Model of Glomerular Size Selectively: Application to Normal and Nephrotic Human," Physiol. Soc., pp. 374-389 (1985).
Haberland et al., "Role of Lysines in Mediating Interaction of Modified Low Density Lipoproteins with the Scavenger Receptor of Human Monocyte Macrophages," J. Biol. Chem. 259:11305-11 (1984).
Habeeb et al., "Molecular Structural Effects Produced in Proteins by Reaction with Succinic Anhydride," Biochem. Biophys. Acta. 29:587-93 (1958).
Heindel et al.,, J. Pharm. Sci., vol. 76, No. 5, (May 1987), pp. 384-386, "Macromolecular Attachment as a Metabolic Stabilizer for a Labile Radiosensitizer".
Andre Trouet et al, "A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: In Vitro and In Vivo Studies", Proc. Natl. Acad. Sci. vol. 79, pp. 626-629, Jan. 1982.
Borden et al, J. Clin, Invest. 69:451-461, 1982.
Abrams Paul G.
Morgan, Jr. Alton C.
Sivam Gowsala P.
Covert John M.
Lovering Richard D.
NeoRx Corporation
Picard Roberta A.
LandOfFree
Alteration of pharmacokinetics of proteins by charge modificatio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of pharmacokinetics of proteins by charge modificatio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of pharmacokinetics of proteins by charge modificatio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2219411